Ferric Carboxymaltose
Generic / Active Ingredient
What is Ferric Carboxymaltose used for?
Iron deficiency anemia
38 Ferric Carboxymaltose brands in Bangladesh
Compare prices across every brand of Ferric Carboxymaltose and pick the most affordable option.
| Brand | Strength | Form | Manufacturer | Price |
|---|---|---|---|---|
| Enrifer | 500 mg/10 ml | IV Injection or Infusion | Beacon Pharmaceuticals Ltd. | ৳ 700.00 |
| Fematos | 500 mg/10 ml | IV Injection or Infusion | General Pharmaceuticals Ltd. | ৳ 700.00 |
| Fematos | 100 mg/2 ml | IV Injection or Infusion | General Pharmaceuticals Ltd. | ৳ 400.00 |
| Fematos | 1 gm/20 ml | IV Injection or Infusion | General Pharmaceuticals Ltd. | ৳ 1,300.00 |
| Ferinject | 100 mg/2 ml | IV Injection or Infusion | Vifor International Ltd. | ৳ 996.74 |
| Ferinject | 500 mg/10 ml | IV Injection or Infusion | Vifor International Ltd. | ৳ 3,114.80 |
| Ferintus | 500 mg/10 ml | IV Injection or Infusion | Beximco Pharmaceuticals Ltd. | ৳ 700.00 |
| Ferintus | 100 mg/2 ml | IV Injection or Infusion | Beximco Pharmaceuticals Ltd. | ৳ 400.00 |
| Ferisen | 500 mg/10 ml | IV Injection or Infusion | Healthcare Pharmaceuticals Ltd. | ৳ 710.00 |
| Ferisen | 100 mg/2 ml | IV Injection or Infusion | Healthcare Pharmaceuticals Ltd. | ৳ 410.00 |
| Ferisen | 1 gm/20 ml | IV Injection or Infusion | Healthcare Pharmaceuticals Ltd. | ৳ 1,300.00 |
| Ferium | 500 mg/10 ml | IV Injection or Infusion | Renata Limited | ৳ 700.00 |
| Ferox | 100 mg/2 ml | IV Injection or Infusion | ACI Limited | ৳ 410.00 |
| Ferox | 500 mg/10 ml | IV Injection or Infusion | ACI Limited | ৳ 700.00 |
| G-Ferric | 500 mg/10 ml | IV Injection or Infusion | Gonoshasthaya Pharma Ltd. | ৳ 400.00 |
| Hemoject | 1 gm/20 ml | IV Injection or Infusion | Nuvista Pharma Ltd. | ৳ 1,300.00 |
| Hemoject | 500 mg/10 ml | IV Injection or Infusion | Nuvista Pharma Ltd. | ৳ 700.00 |
| Hemorise | 1 gm/20 ml | IV Injection or Infusion | ACME Laboratories Ltd. | ৳ 1,300.00 |
| Hemorise | 500 mg/10 ml | IV Injection or Infusion | ACME Laboratories Ltd. | ৳ 700.00 |
| Hemorise | 100 mg/2 ml | IV Injection or Infusion | ACME Laboratories Ltd. | ৳ 410.00 |
| Injefer | 1 gm/20 ml | IV Injection or Infusion | Opsonin Pharma Ltd. | ৳ 1,300.00 |
| Injefer | 100 mg/2 ml | IV Injection or Infusion | Opsonin Pharma Ltd. | ৳ 400.00 |
| Injefer | 500 mg/10 ml | IV Injection or Infusion | Opsonin Pharma Ltd. | ৳ 700.00 |
| Iroject | 500 mg/10 ml | IV Injection or Infusion | Popular Pharmaceuticals Ltd. | ৳ 700.00 |
| Maltofer | 750 mg/15 ml | IV Injection or Infusion | Incepta Pharmaceuticals Ltd. | ৳ 1,000.00 |
| Maltofer | 1 gm/20 ml | IV Injection or Infusion | Incepta Pharmaceuticals Ltd. | ৳ 1,300.00 |
| Maltofer | 500 mg/10 ml | IV Injection or Infusion | Incepta Pharmaceuticals Ltd. | ৳ 700.00 |
| Maltofer | 100 mg/2 ml | IV Injection or Infusion | Incepta Pharmaceuticals Ltd. | ৳ 400.00 |
| Maxfer | 1 gm/20 ml | IV Injection or Infusion | Eskayef Pharmaceuticals Ltd. | ৳ 1,300.00 |
| Maxfer | 500 mg/10 ml | IV Injection or Infusion | Eskayef Pharmaceuticals Ltd. | ৳ 700.00 |
| Oxyfer | 1 gm/20 ml | IV Injection or Infusion | Ibn Sina Pharmaceuticals Ltd. | ৳ 1,300.00 |
| Oxyfer | 750 mg/15 ml | IV Injection or Infusion | Ibn Sina Pharmaceuticals Ltd. | ৳ 1,000.00 |
| Oxyfer | 500 mg/10 ml | IV Injection or Infusion | Ibn Sina Pharmaceuticals Ltd. | ৳ 700.00 |
| Revofer | 750 mg/15 ml | IV Injection or Infusion | Square Pharmaceuticals Ltd. | ৳ 1,000.00 |
| Revofer | 500 mg/10 ml | IV Injection or Infusion | Square Pharmaceuticals Ltd. | ৳ 700.00 |
| Xefer | 1 gm/20 ml | IV Injection or Infusion | Ziska Pharmaceuticals Ltd. | ৳ 1,300.00 |
| Xefer | 100 mg/2 ml | IV Injection or Infusion | Ziska Pharmaceuticals Ltd. | ৳ 400.00 |
| Xefer | 500 mg/10 ml | IV Injection or Infusion | Ziska Pharmaceuticals Ltd. | ৳ 700.00 |
Indication DetailsView
Ferric Carboxymaltose is indicated for the treatment of iron deficiency anemia in adult patients-
- Who have intolerance to oral iron or have had unsatisfactory response to oral iron
- Who have non-dialysis dependent chronic kidney disease.
Therapeutic ClassView
Parenteral Iron Preparations
PharmacologyView
Non-dextran, IV is a colloidal iron hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron; replaces iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin Macrophage engulf FCM from blood and control iron release. Transferrin saturates and, Iron into the liver, spleen and Bone marrow.
DosageView
For patients weighing 50 kg or more: Give Ferric Carboxymaltose in two doses separated by at least 7 days. Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course.
For patients weighing less than 50 kg: Give Ferric Carboxymaltose in two doses separated by at least 7 days. Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course.
The dosage of Ferric Carboxymaltose is expressed in mg of elemental iron. Each mL of Ferric Carboxymaltose contains 50 mg of elemental iron. Ferric Carboxymaltose treatment may be repeated if iron deficiency anemia reoccurs.
Administer Ferric Carboxymaltose intravenously, either as an undiluted slow intravenous push or by infusion. When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes.
When added to an infusion bag containing 0.9% Sodium Chloride Injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Ferric Carboxymaltose solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL.
Inspect parenteral drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Ferric Carboxymaltose is intended for single use only. Any unused drug remaining after injection must be discarded.
Avoid extravasation of Ferric Carboxymaltose since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Ferric Carboxymaltose administration at that site.
For patients weighing less than 50 kg: Give Ferric Carboxymaltose in two doses separated by at least 7 days. Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course.
The dosage of Ferric Carboxymaltose is expressed in mg of elemental iron. Each mL of Ferric Carboxymaltose contains 50 mg of elemental iron. Ferric Carboxymaltose treatment may be repeated if iron deficiency anemia reoccurs.
Administer Ferric Carboxymaltose intravenously, either as an undiluted slow intravenous push or by infusion. When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes.
When added to an infusion bag containing 0.9% Sodium Chloride Injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Ferric Carboxymaltose solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL.
Inspect parenteral drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Ferric Carboxymaltose is intended for single use only. Any unused drug remaining after injection must be discarded.
Avoid extravasation of Ferric Carboxymaltose since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Ferric Carboxymaltose administration at that site.
Side EffectsView
Nausea, Hypertension, Flushing, Decreased blood phosphorus, Dizziness, Vomiting, Pruritus, Rash, Urticaria, Wheezing, Injection site discoloration, Headache, Increased alanine aminotransferase), Dysgeusia, Hypotension, Constipation, Serious anaphylactic/anaphylactoid reactions
ContraindicationsView
Hypersensitivity to any of its components.
PrecautionsView
Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Ferric carboxymaltose. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Ferric carboxymaltose administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Ferric carboxymaltose when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but not limited to, pruritus, rash, urticaria, wheezing, or hypotension may occur.
Hypertension: Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Ferric carboxymaltose administration.
Hypertension: Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Ferric carboxymaltose administration.
InteractionsView
There are no known drug interactions and none well documented.
Pregnancy & LactationView
Pregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks
Storage ConditionsView
Do not store above 30°C. Do not freeze.